» Articles » PMID: 22807631

Active Home-based Cancer Treatment

Abstract

Background: Active home-based treatment represents a new model of health care. Chronic treatment requires continuous access to facilities that provide cancer care, with considerable effort, particularly economic, on the part of patients and caregivers. Oral chemotherapy could be limited as a consequence of poor compliance and adherence, especially by elderly patients.

Methods: We selected 30 cancer patients referred to our department and treated with oral therapy (capecitabine, vinorelbine, imatinib, sunitinib, sorafenib, temozolomide, ibandronate). This pilot study of oral therapy in the patient's home was undertaken by a doctor and two nurses with experience in clinical oncology. The instruments used were clinical diaries recording home visits, hospital visits, need for caregiver support, and a questionnaire specially developed by the European Organization for Research and Treatment of Cancer (EORTC), known as the QLQ-C30 version 2.0, concerning the acceptability of oral treatment from the patient's perspective.

Results: This program decreased the need to access cancer facilities by 98.1%, promoted better quality of life for patients, as reflected in increased EORTC QLQ-C30 scores over time, allowing for greater adherence to oral treatment as a result of control of drug administration outside the hospital. This model has allowed treatment of patients with difficult access to care (elderly, disabled or otherwise needed caregivers) that in the project represent the majority (78% of these).

Conclusions: This model of active home care improves quality of life and adherence with oral therapy, reduces the need to visit the hospital, and consequently decreases the number of lost hours of work on the part of carers. Management of the service by the professionals involved revealed excellent control of the process by nursing staff, with minimal visits involving doctors.

Citing Articles

Domains of Structured Oral Anticancer Medication Programs: A Scoping Review.

Sivakumaran K, Ginex P, Waseem H, Belcher S, Lagler-Clark S, LeFebvre K Oncol Nurs Forum. 2022; 49(4):296-306.

PMID: 35788732 PMC: 9303043. DOI: 10.1188/22.ONF.296-306.


ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.

Belcher S, Mackler E, Muluneh B, Ginex P, Anderson M, Bettencourt E Oncol Nurs Forum. 2022; 49(4):279-295.

PMID: 35788731 PMC: 9303042. DOI: 10.1188/22.ONF.279-295.


"It's a part of the patient": The experiences of patients with cancer undergoing home-based chemotherapy from patients' and nurses' perspectives.

Jang H, Kim S, Kim D, Park M, Rhue S, Lee C Asia Pac J Oncol Nurs. 2022; 9(8):100072.

PMID: 35692730 PMC: 9184288. DOI: 10.1016/j.apjon.2022.04.011.


Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall.

Tralongo P, Gebbia V, Mercadante S, Bordonaro R, Ferrau F, Barni S Cancers (Basel). 2021; 13(8).

PMID: 33923380 PMC: 8071576. DOI: 10.3390/cancers13081919.


Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients.

Chini C, Bascialla L, Giaquinto A, Magni E, Gobba S, Proserpio I Support Care Cancer. 2020; 29(2):917-923.

PMID: 32533437 DOI: 10.1007/s00520-020-05569-9.


References
1.
Tralongo P, Ferrau F, Borsellino N, Verderame F, Caruso M, Giuffrida D . Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag. 2011; 7:387-92. PMC: 3176172. DOI: 10.2147/TCRM.S22119. View

2.
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

3.
Lee J, Grace K, Taylor A . Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006; 296(21):2563-71. DOI: 10.1001/jama.296.21.joc60162. View

4.
Oliveira E, Melo E, Pinheiro R, Noronha C, Carvalho M . [Access to cancer care: mapping hospital admissions and high-complexity outpatient care flows. The case of breast cancer]. Cad Saude Publica. 2011; 27(2):317-26. DOI: 10.1590/s0102-311x2011000200013. View

5.
Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View